Trastuzumab for the Treatment of Non-Small-Cell Lung Cancer

Annals of Pharmacotherapy

Volumn 37, Issue 12, 2003, Pages 1904-1908

  Ferrone, Marcus ^a   Motl, Susannah E ^b  

^a Drug Information   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Herceptin; Non small cell lung cancer; Trastuzumab

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

ANEMIA; BLOOD TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; EMBASE; EVALUATION; FATIGUE; HUMAN; INJECTION SITE; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MEDLINE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II; HUMANS; LUNG NEOPLASMS;

EID: 0345275882     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D101     Document Type: Review

References (25)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43. Erratum 2001;2:596.
2. Jemal A, Murry T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Carney DN. Lung cancer - time to move on from chemotherapy. N Engl J Med 2002;346:126-8.
4. Ginsberg RJ, Vokes EE, Rosenzweig K. Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practices of oncology. Philadelphia: Lippincott-Raven, 2001:925-82.
5. Evans TL, Lynch TJ. Lung cancer. Oncologist 2001;6:407-14.
6. American Joint Committee on Cancer. Fleming D, ed. Manuals of staging for cancer. Philadelphia: Lippincott-Raven, 1997.
7. Kelly K, Crowley J, Bunn PA, Presant CA, Grevsta PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
8. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
9. Package insert. Herceptin (trastuzumab). South San Franscisco, CA: Genentech, August 2002.
10. Azzoli CG, King LM, Miller VA, Kris MG, Mass R. Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol 2002;29(suppl 4):59-65.
11. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. C-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994;54:3260-6.
12. Noguchi M, Murakami M, Bennett W, Lupu R, Hui F Jr, Harris CC, et al. Biological consequences of overexpression of a transfected c-erb B-2 gene in immortalized human bronchial epithelial cells. Cancer Res 1993;53:2035-43.
13. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney I, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-7.
14. Sliwkowski MS, Lofgren JA, Lews GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
15. Bunn PA Jr, Helfrich B, Soriano AF. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001;7:3239-50.
16. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/neu expression in malignant lung tumors. Semin Oncol 2002;29 (suppl 4):51-8.
17. Dacic S, Ramalingam S, Luketich J, Cieply K, Yousem S, Belani CP. Fluorescent in situ hybridization (FISH) evaluation of HER-2/neu, and cyclin D1 expression in non-small cell lung cancer (NSCLC): correlation with clinical behavior (abstract 2622). Proc Am Soc Clin Oncol 2003;22:652.
18. Scheurle D, Jahanzeb M, Aronsohn RS, Watzek L, Narayanan R. HER-2/neu expression in archival non-small cell lung cancer carcinoma using FDA-approved Hercep test. Anticancer Res 2000;20(30B):2091-6.
19. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002;37:17-27.
20. Schiller J, Langer JC, Thor A, Johnson DH, Vangel M, Huang C, et al. Trastuzumab in combination with paclitaxel/carboplatin advanced non-small cell lung cancer: final report of ECOG 2598 (abstract 2606). Proc Am Soc Clin Oncol 2003;22:648.
21. King LM, Miller VA, Crapanzano J, Ng KK, Pizzo B, Tyson L, et al. Randomized Phase II trial of trastuzumab (Tras) plus either weekly docetaxel (Doc) or paclitaxel (Pac) in previously untreated advanced non-small cell lung cancer (NSCLC) (abstract 1328). Proc Am Soc Clin Oncol 2001;20:333a.
22. Patel JD, Krug LM, Crapanzano J, Pizzo B, Tyson L, Azzoli CG, et al. Clinical characteristics and outcomes of patients with advanced non-small cell lung cancer treated with trastuzumab plus either weekly docetaxel or paclitaxel (poster). Presented at: Annual Meeting of American Society of Clinical Oncology, Orlando, FL, May 18-20, 2002.
23. Tran HT, Herbst RS, Glisson BS, Pisters KM, Khuri FR, Oh YW, et al. Herceptin in combination with cisplatin and gemcitabine in patient (pts) with HER2 overexpressing, untreated, advanced, non-small cell lung cancer (NSCLC): final report of a phase II trial (abstract 1226). Proc Am Soc Clin Oncol 2002;21:307a.
24. Zinner RG, Glisson BS, Pisters KM, Khuri FR, Oh YW, Ro JY, et al. Cisplatin and gemcitabine combined with Herceptin in patients (Pts) with HER2 overexpressing, untreated, advanced, non-small cell lung cancer (NSCLC); a Phase II trial (abstract 1307). Proc Am Soc Clin Oncol 2001;20:328a.
25. Gatzemeier U, Groth G, Hirsch V, Butts CA, Van Zandwijk N, Shepherd F, et al. Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer overexpressing HER2: results of a randomized phase II study (abstract 1185). Proc Am Soc Clin Oncol 2002;21:297a.